MDC.AU · Medlab Clinical Limited

-

Please sign in to comment on MDC.AU

1 Comment

Admin

4 years, 1 month ago

Medlab Clinical Limited is currently in a long term downtrend where the price is trading 31.8% below its 200 day moving average.

From a valuation standpoint, the stock is 93.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.4.

Medlab Clinical Limited's total revenue rose by 57.4% to $4M since the same quarter in the previous year.

Its net income has increased by 25.4% to $-5M since the same quarter in the previous year.

Finally, its free cash flow grew by 42.2% to $-2M since the same quarter in the previous year.

Based on the above factors, Medlab Clinical Limited gets an overall score of 4/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU000000MDC8
Sector	Healthcare
Industry	Biotechnology

Beta	0.91
Market Cap	15M
PE Ratio	0.0
Target Price	18.84
Dividend Yield	0.0%

ABOUT

Medlab Clinical Limited

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.

MDC.AU · Medlab Clinical Limited

-

Medlab Clinical Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Medlab Clinical Limited using a moving average strategy